title: Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
abstract: BACKGROUND
  Fcgamma receptors (FcgammaRs) are potent immune modulators. FcgammaR genes encompass a complex region, polymorphic by both single nucleotide polymorphisms (SNPs) and copy number variation (CNV). The heterogeneity of rheumatoid arthritis (RA) combined with the genetic complexity of FcgammaR genes may be the cause of inconsistent findings in previous RA studies on FcgammaR SNPs. There is increasing evidence that anti-citrullinated peptide antibody (ACPA)-positive RA and ACPA-negative RA have a different genetic background.
  
  
  OBJECTIVE
  To investigate whether FcgammaRIIIA 158V/F SNP associates differently with ACPA-positive and ACPA-negative RA and to assess if the FcgammaRIIIA gene CNV affects the association of the FcgammaRIIIA 158V/F SNP with RA and whether the FcgammaRIIIA gene CNV confers risk for RA.
  
  
  METHODS
  945 patients with RA and 388 healthy controls, all Dutch-Caucasians, were included in the study. FcgammaRIIIA 158V/F SNP was genotyped using Sequenom. CNV of the FcgammaRIIIA gene was determined in 456 patients with RA and 285 controls using multiplex ligation-dependent probe amplification. Associations between genotypes and RA were analysed, stratifying for the presence/absence of ACPA and CNV.
  
  
  RESULTS
  In all patients with RA the FcgammaRIIIA 158V/F SNP was not associated with RA. In ACPA-positive RA (n = 358), the VV genotype was more prevalent in cases than in controls (18.4% vs 13.2%, OR = 1.5, p = 0.05). After stratification for CNV the VV genotype was associated with RA in general (n = 426) (OR = 1.6, 95% CI 0.97 to 2.6, p = 0.05) and with ACPA-positive RA (n = 135) (OR = 2.1, 95% CI 1.2 to 3.8, p = 0.009) but not with ACPA-negative RA. The distribution of CNV was not significantly different between patients with RA and controls.
  
  
  CONCLUSIONS
  The FcgammaRIIIA 158 VV genotype confers risk for ACPA-positive RA; this association increased slightly after correction for CNV of the FcgammaRIIIA gene. CNV itself is not associated with RA susceptibility.
authors.affiliation: Department of Rheumatology, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands. m.thabet@lumc.nl
authors.forename: M M
authors.initials: MM
authors.lastname: Thabet
authors.forename: T W J
authors.initials: TW
authors.lastname: Huizinga
authors.forename: R B
authors.initials: RB
authors.lastname: Marques
authors.forename: G
authors.initials: G
authors.lastname: Stoeken-Rijsbergen
authors.forename: A M
authors.initials: AM
authors.lastname: Bakker
authors.forename: F A
authors.initials: FA
authors.lastname: Kurreeman
authors.forename: S J
authors.initials: SJ
authors.lastname: White
authors.forename: R E M
authors.initials: RE
authors.lastname: Toes
authors.forename: A H M
authors.initials: AH
authors.lastname: van der Helm-van Mil
mesh_terms: D001172:Arthritis, Rheumatoid / Q000235:genetics* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D018628:Gene Dosage / Q000235:genetics*; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D010375:Pedigree; D010456:Peptides, Cyclic / Q000276:immunology*; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics*
chemical_list: D001323:Autoantibodies; C496124:FCGR3A protein, human; D010456:Peptides, Cyclic; D017452:Receptors, IgG; C487763:cyclic citrullinated peptide